Biobanking Market 2021: Global Industry Exhibits Huge Growth by Top Key Players
The advances observed in genomics are predicted to enhance
the progress of the biobanking market. Reports created by MRFR detail the
developments in the industry that can be expected in the market through the
forecast period. The Biobanking
Market is estimated to show a 7.6% CAGR During The Forecast Period.
The availability of advanced devices and significant
breakthroughs in life sciences is predicted to spur the biobanking market
companies in the impending period. Furthermore, the implementation of important
research in several areas is predicted to influence the assessment period's
biobanking market. The development of regenerative medicine demand is projected
to enhance the biobanking market in the near future.
Detailed Regional Analysis
The biobanking market's regional assessment consists of
Europe, the Middle East, Asia Pacific, Americas, and Africa. The Americas
region's biobanking market is primarily motivated by the growing number of
research pursuits in genomics, mounting financing in healthcare, and growing
patient residents suffering from chronic illnesses. The European region's
biobanking market displays development with escalating stress on research and
developmental activities for development in diagnosis and medication methods.
The Asia Pacific biobanking market is anticipated to be the speediest growing
market whose development is accredited to the increasing load of chronic
diseases and growing emphasis on early diagnosis and handling of rare diseases.
Additionally, other influences backing the market's advance are lifestyle
changes, the effect of western culture amongst adults, and compulsion to
smoking.
Competitive Analysis
The investment trend
in the market is projected to display a trend of mergers and acquisitions. The
role of government bodies is estimated to be essential to the development of
the market. The presence of online channels is predicted to enhance the
market's advancement in the upcoming years. The market is estimated to profit
from the contenders' overall contribution who are having different fortes for
growth. The buoyancy in market sentiment will act as a tool for future growth.
The role of innovation is estimated to become even more important for progress
as the market grows. The improvement in trade and distribution policies is
further anticipated to motivate the market's development in the upcoming
period. The expansion of geographical footprint is estimated to tap into
undiscovered segments is likely to have a favorable effect on the market
developments. The effect of novelty and effective pricing policies will help
the global market return to an optimal functioning level in the forecast
period.
The prominent companies in the biobanking market are Greiner
Holding AG, Thermo Fisher Scientific Inc., Brooks Automation, Inc., Qiagen
N.V., Promega Corporation, Merck KGaA, VWR Corporation, Tecan Trading AG,
Becton Dickinson and Company, Panasonic Healthcare Holdings Co., Ltd, Hamilton
Company, Chart Industries, Inc., and others.
Segmental Analysis
The segmental scrutiny of the biobanking market is carried
out on the basis of products and services, sample type, storage type,
application, end user and region. The
products and services segment of the biobanking market consists of consumables,
services, equipment, and biobanking
software. The region segment of the biobanking market consists of Europe,
the Middle East, Asia Pacific, Americas, and Africa. The sample type segment of
the biobanking market consists of human tissues, cell lines, blood products,
nucleic acids, and biological fluids. The biobanking market's application
segment consists of life science research, regenerative medicine, and clinical
research. The end-user segment of the biobanking market consists of diagnostic
laboratories, hospitals, and research centers. The storage type segment of the
biobanking market consists of automated storage and manual storage.
Industry Updates:
Feb 2021 Cincinnati Children's Hospital Medical Center has
joined forces with Down Syndrome Achieves (DSA) to unveil a research biobank,
which assists as a central source for biospecimens contributed by persons with
Down syndrome and their immediate relations. The DSA Biobank targets to recover
clinical care and health consequences for individuals with Down syndrome and
others by covering well-annotated, high-quality biospecimens that help in
driving basic, translational, and clinical study.
Oct 2020 GoodCell, which advances small-panel genetic
testing, personal biobanking, and analysis, recently announced that it had
solicited USD 17.9 million in novel venture capital. Intellectual Digital,
Prairie Fire Capital, and numerous individual investors contributed to the
round. The company would use the backing to support athe expansion of the
firm's analytics platform and its technology for sensing and nursing
accumulated genetic disparity within blood cells. The company also seeks to enlarge
its personal biobanking service and add to its list of personalized health
screening contribution options.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to
unravel the complexity of various industries through our Cooked Research Report
(CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR
team have supreme objective to provide the optimum quality market research and
intelligence services to our clients.
Contact us:
Market Research Future (part of Wantstats Research and Media
Private Limited),
99 Hudson Street,5Th Floor, New York, New York 10013,
United States of America
+1 646 845 9312
Email: sales@marketresearchfuture.com

Comments
Post a Comment